Drugs / Fufang Congrong Yizhi Capsules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06673602 | Nov 2024 → Jun 2026 overdue | cognitive impairment with or without cerebellar ataxia, intracerebral hemorrhage | Qinhuangdao Hospital of Traditional Chinese Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fufang Congrong Yizhi Capsules | “The experimental group receive conventional treatment and oral administration of Fufang Congrong Yizhi Capsules (FCYC) for 12 weeks” NCT06673602 ↗ |
| Known as | FCYC | “The experimental group receive conventional treatment and oral administration of Fufang Congrong Yizhi Capsules (FCYC) for 12 weeks” NCT06673602 ↗ |
| Route | Oral | “oral administration of FCYC (four capsules, three times a day, orally)” NCT06673602 ↗ |